MediGene Announces Approval of Veregen® in Spain

March 30, 2011 MediGene AG / MediGene Announces Approval of Veregen® in Spain . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Martinsried/Munich, March 30, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) today announces that Veregen(®) has obtained market approval from the Spanish regulatory authority (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS), for the treatment of genital warts. Market launch of Veregen(®) in Spain by MediGene's partner Juste S.A.Q.F. is scheduled to take place in the first quarter of 2012, upon conclusion of the price fixing procedure, which is conducted in conjunction with the Dirección General de Farmacia y Productos Sanitarios. Veregen(®) is currently available on the US, German, and Austrian markets. A second wave of applications for market approval within the European mutual recognition procedure is planned, with Germany serving as the reference member state in this process. MediGene has already entered into several marketing partnerships for Veregen(®), e.g. with Nycomed for the US, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, and with a number of other partners across Europe, Latin America, and Asia. MediGene is planning to continue this global licensing strategy. Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment) for the topical treatment of external genital warts is a concentrate of catechins with a complex defined composition, extracted from green tea leaves. MediGene acquired the basic rights to the active ingredient in Veregen(®) from the Canadian company Epitome Pharmaceuticals, Ltd. in 1999, and was solely responsible for the drug's successful preclinical and clinical development, as well as the approval process. Patent protection has also been further upgraded by a number of proprietary inventions. Sinecatechins 15% ointment (Veregen(®)) is now also recommended as a treatment option in the US Department of Health and Human Services' Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines 2010 for the treatment of genital warts. This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene(®) and Veregen(®) are registered trademarks of MediGene AG. Polyphenon E(®) is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only. - ends - MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to have revenues from marketed products. It has several drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs, with a focus on oncology. Contact MediGene AG Julia Hofmann, Kerstin Langlotz Investor & Public Relations Tel.: +49 - 89 - 85 65 - 33 01 Fax: +49 - 89 - 85 65 - 29 20 Email: investor@medigene.com --- End of Message --- MediGene AG Lochhamer Strasse 11 Martinsried / München Germany WKN: 502090;ISIN: DE0005020903; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse; This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MediGene AG via Thomson Reuters ONE [HUG#1501510]